EhabLAtallahMD

Oncology • Milwaukee, WI

Hematologic Oncology

Professor, Medicine, Medical College of Wisconsin

Join to view full profile

Dr. Atallah is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Atallah's full profile

Already have an account?

Office
9200 W Wisconsin Ave
Neoplastic Diseases
Milwaukee, WI 53226
Phone+1 414-805-6800

Fax+1 414-805-6805
Is this information wrong?

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 2003 - 2004
Cleveland Clinic Foundation/Fairview HospitalResidency, Internal Medicine, 2000 - 2003
Cairo University School of MedicineClass of 1994

Certifications & Licensure

WI State Medical License 2007 - 2025
MI State Medical License 2003 - 2008
OH State Medical License 2000 - 2003

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) Start of enrollment: 2009 Mar 01
Completed
Phase 1
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Completed
Phase 2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia Start of enrollment: 2013 Jun 01
Terminated
Phase 1
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
Active, not recruiting
Phase 3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Start of enrollment: 2017 Jun 05
Completed
Phase 2
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2017 Jun 14
Recruiting
Phase 2
Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation Start of enrollment: 2021 Nov 11
Recruiting
Phase 2
XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia Start of enrollment: 2022 Feb 02
Recruiting
Phase 1
Roles: Sponsor-Investigator
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors Start of enrollment: 2019 Nov 19
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Start of enrollment: 2022 Apr 22
Recruiting
Phase 2
Roles: Contact
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH Start of enrollment: 2021 Feb 28
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment Start of enrollment: 2023 Oct 23
Not yet recruiting
Phase 2
Roles: Contact, Study Chair
Join now to see all

Publications & Presentations

PubMed

A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Guru Subramanian Guru Murthy, Antoine N Saliba, Aniko Szabo, Alexandra Harrington, Sameem Abedin, Karen Carlson, Laura Michaelis, Lyndsey Runaas, Arielle Baim, Alex Hi...> ;Haematologica. 2024 Apr 4
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eig...
Yasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy, Rory M Shallis, Andrew H Matthews, Talha Badar, Emily M Geramita, Vamsi K Kota, Alok Swaroop, Peter Doukas, D...> ;American Journal of Hematology. 2024 Apr 1
Evaluating population-level outcomes in Chronic Lymphocytic leukemia in the era of novel therapies using the SEER registry.
Ravi Narra, Wanlin Juan, Aniko Szabo, Guru Subramanian Guru Murthy, Chandrasekar Muthiah, Ehab Atallah> ;Leukemia Research. 2024 Mar 22
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: resul...
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Patel, Jan P Bewersdorf, Adam S ...> ;Blood Cancer Journal. 2024 Feb 20
1 citations
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.
Winn, A., Deininger, M., Moore, J., Shah, N., Flynn, K., Atallah, E., Cortes, J., Kota, V., Larson, R., Mauro, M., Oehler, V., Pinilla-Ibarz, J., Radich, J., Thompson, J.> ;JAMA Network Open. 2023 Dec 1
Eligibility criteria: too big, too small or just right?
Ehab Atallah> ;Haematologica. 2024 Apr 1
Real-world Management of CML: Outcomes and Treatment Patterns.
Nicole Held, Ehab L Atallah> ;Current Hematologic Malignancy Reports. 2023 Oct 1
Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiv...
Skyler Taylor, Guru Subramanian Guru Murthy, Lyndsey Runaas, Laura C Michaelis, Karen Carlson, Ehab L Atallah, Sameem M Abedin> ;Leukemia Research. 2023 Sep 1
Proposals for Clinical Trials in Chronic Myelomonocytic Leukemia.
Alexandra Rezazadeh, Michael Deininger, Ehab Atallah> ;Current Treatment Options in Oncology. 2023 Aug 1
3 citations
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis.
Sara Zarnegar-Lumley, Todd A Alonzo, Robert B Gerbing, Megan Othus, Zhuoxin Sun, Rhonda E Ries, Jim Wang, Amanda Leonti, Matthew A Kutny, Fabiana Ostronoff, Jerald P R...> ;Blood Advances. 2023 Oct 10
Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia.
Guru Subramanian Guru Murthy, Ehab Atallah> ;Hematology/oncology and Stem Cell Therapy. 2023 May 23
SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML).
Sherrie Mikhaeel, Ehab Atallah> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 May 1
11 citations
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Cons...
Talha Badar, Ehab Atallah, Rory Shallis, Antoine N Saliba, Anand Patel, Jan P Bewersdorf, Justin Grenet, Maximilian Stahl, Adam Duvall, Madelyn Burkart, Neil Palmisian...> ;Leukemia. 2023 Apr 1
3 citations
Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibit...
Ehab Atallah, Michael J Mauro, Andreas Hochhaus, Carla Boquimpani, Yosuke Minami, Vikalp Kumar Maheshwari, Lovneet Saini, Regina Corbin, Delphine Réa> ;Journal of Cancer Research and Clinical Oncology. 2023 Aug 1
A Survey of Patient Experience in CML: American and Canadian Perspectives.
Christopher Hillis, Kathryn E Flynn, Erinn Hoag Goldman, Tracy S Moreira-Lucas, Josie Visentini, Stephanie Dorman, Rachel Ballinger, Hilary F Byrnes, Andrea De Palma, ...> ;Patient Preference and Adherence. 2023 Jan 1
Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review.
Ehab Atallah, Lovneet Saini, Rodrigo Maegawa, Tanvi Rajput, Regina Corbin, Ricardo Viana> ;Therapeutic Advances in Hematology. 2023 Jan 1
9 citations
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versu...
Alexander E Perl, Richard A Larson, Nikolai A Podoltsev, Stephen Strickland, Eunice S Wang, Ehab Atallah, Gary J Schiller, Giovanni Martinelli, Andreas Neubauer, Jorge...> ;Transplantation and Cellular Therapy. 2023 Apr 1
2 citations
Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia.
Sameem M Abedin, Talha Badar, Katelyn Gauger, Laura C Michaelis, Lyndsey Runaas, Karen-Sue Carlson, Gs Guru Murthy, Ehab Atallah> ;Leukemia Research. 2022 Dec 1
4 citations
Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular T...
Zachariah DeFilipp, Stefan O Ciurea, Corey Cutler, Marie Robin, Erica D Warlick, Ryotaro Nakamura, Andrew M Brunner, Bhagirathbhai Dholaria, Alison R Walker, Nicolaus ...> ;Transplantation and Cellular Therapy. 2023 Feb 1
8 citations
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia.
Anjali S Advani, Anna Moseley, Kristen M O'Dwyer, Brent L Wood, Jae Park, Matthew Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab L Atallah, Aaron T Gerds, Susan M O...> ;Blood Advances. 2023 Apr 11
4 citations
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.
Kathryn E Flynn, Ehab Atallah, Li Lin, Neil P Shah, Richard T Silver, Richard A Larson, Javier Panilla-Ibarz, James E Thompson, Vivian G Oehler, Jerald P Radich, Vamsi...> ;Haematologica. 2022 Nov 1
Low-intensity induction in acute myeloid leukemia. Always in the patients' best interest?
Ehab Atallah> ;Haematologica. 2023 Apr 1
24 citations
Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.
Talha Badar, Ehab Atallah, Rory M Shallis, Aaron D Goldberg, Anand Patel, Yasmin Abaza, Jan P Bewersdorf, Antoine N Saliba, Guilherme Sacchi De Camargo Correia, Guru M...> ;American Journal of Hematology. 2022 Jul 1
4 citations
A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative ...
Athena Dong, Xiaoqing Pan, Chien-Wei Lin, Yi-Wen Huang, Hayden Krause, Pan Pan, Arielle Baim, Michael J Thomas, Xiao Chen, Jianhua Yu, Laura Michaelis, Pengyuan Liu, L...> ;Journal of Cancer Prevention. 2022 Jun 30
49 citations
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
Alexander E Perl, Richard A Larson, Nikolai A Podoltsev, Stephen Strickland, Eunice S Wang, Ehab Atallah, Gary J Schiller, Giovanni Martinelli, Andreas Neubauer, Jorge...> ;Blood. 2022 Jun 9
Join now to see all

Abstracts/Posters

Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Population Level Outcomes of Chronic Lymphocytic Leukemia in the Era of Targeted Agents- Analysis of Surveillance Epidemiology and End Results (SEER) Database
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Population Level Outcomes of Chronic Lymphocytic Leukemia in the Era of Targeted Agents- Analysis of Surveillance Epidemiology and End Results (SEER) Database
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Na¥ve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive...
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study
Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Building a National CML Registry
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Systematic Screening for Familial Leukemia Based on Somatic Genomic Profiling Results
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Reducing Venous Thrombosis with Antithrombin Supplementation in Patients Undergoing Treatment for ALL with Asparaginase Based Regimens
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Authored Content

Efficacy and Safety Outcomes by Baseline Comorbidity and Age in Patients Newly Diagnosed with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Treated with Dasatinib or Imatinib in DASISIONOctober 2017

Press Mentions

Off Their Pricey CML Meds, Many ThriveJanuary 20th, 2023
When Is It Safe to Discontinue TKI Therapy in People with Chronic Myeloid Leukemia?March 20th, 2022
Clinical Edge Journal Scan Commentary: AML August 2021August 2nd, 2021
Join now to see all